ATRX and central nervous system cancer: ATRX is frequently mutated in GBM, and CRISPR-Cas9 ATRX knockout suppresses cell proliferation, invasion, and vasculogenic mimicry in glioma cells, resulting in increased sensitivity to TMZ by enhancing TMZ-induced DNA damage and apoptosis [241].